Payment overview · 2025
General Payments
$2,340.27
85 reported records · 12 companies
Healthcare provider profile · identity verified
Sadegh Salmassi, MD
Allopathic & Osteopathic Physicians|General Practice · DELANO, CA · NPI 1831361583
Verified facts
What the public records show
CMS Open Payments records show Sadegh Salmassi, MD received $2,340.27 in general payments during 2025 across 85 reported records.
Aimmune Therapeutics, Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Rexulti, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 535 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $617.90 | 26.4% | 31 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $497.63 | 21.3% | 12 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $338.91 | 14.5% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $317.14 | 13.6% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.57 | 6.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 5.3% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $114.64 | 4.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.00 | 2.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $52.26 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.62 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.63 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.97 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,340.27 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $547.64 | 28 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $446.84 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $338.91 | 25 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $227.43 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $193.55 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $192.14 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $176.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $149.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $114.64 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $70.26 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 129 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 302 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 535 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
535 | 46 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
302 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
302 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 992 | 109 |
| Losartan Potassium | Losartan Potassium | 837 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 647 | 97 |
| Metformin Hcl | Metformin Hcl | 618 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 75 |
| Gabapentin | Gabapentin | 573 | 60 |
| Omeprazole | Omeprazole | 560 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 536 | 96 |
| Linzess | Linaclotide | 535 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 528 | 100 |
| Donepezil Hcl | Donepezil Hcl | 443 | 36 |
| Naproxen | Naproxen | 413 | 89 |
| Allopurinol | Allopurinol | 391 | 71 |
| Tradjenta | Linagliptin | 382 | 44 |
| Furosemide | Furosemide | 381 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 364 | 49 |
| Simvastatin | Simvastatin | 321 | 57 |
| Lisinopril | Lisinopril | 316 | 65 |
| Jardiance | Empagliflozin | 302 | 42 |
| Finasteride | Finasteride | 295 | 31 |
| Spironolactone | Spironolactone | 282 | 30 |
| Glimepiride | Glimepiride | 281 | 58 |
| Eliquis | Apixaban | 265 | 16 |
| Januvia | Sitagliptin Phosphate | 257 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 210 | 30 |
| Levetiracetam | Levetiracetam | 205 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 19 |
| Vascepa | Icosapent Ethyl | 176 | 40 |
| Memantine Hcl | Memantine Hcl | 163 | 12 |
| Celecoxib | Celecoxib | 154 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 141 | suppressed |
| Carvedilol | Carvedilol | 139 | 17 |
| Divalproex Sodium | Divalproex Sodium | 136 | suppressed |
| Potassium Chloride | Potassium Chloride | 131 | 15 |
| Farxiga | Dapagliflozin Propanediol | 129 | 25 |
| Montelukast Sodium | Montelukast Sodium | 129 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 12 |
| Baclofen | Baclofen | 122 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 121 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 119 | 35 |
| Carbamazepine | Carbamazepine | 118 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 21 |
| Meloxicam | Meloxicam | 109 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 106 | 38 |
| Ibuprofen | Ibuprofen | 102 | 40 |
| Azithromycin | Azithromycin | 101 | 86 |
| Famotidine | Famotidine | 101 | 12 |
| Buspirone Hcl | Buspirone Hcl | 100 | 16 |
| Enulose | Lactulose | 95 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 95 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 92 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 13 |
| Midodrine Hcl | Midodrine Hcl | 91 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 84 | suppressed |
| Cephalexin | Cephalexin | 79 | 57 |
| Ozempic | Semaglutide | 77 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 73 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 72 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 50 |
| Fenofibrate | Fenofibrate,micronized | 68 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Levofloxacin | Levofloxacin | 66 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 64 | 13 |
| Glipizide | Glipizide | 64 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 64 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | suppressed |
| Folic Acid | Folic Acid | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 16 |
| Kerendia | Finerenone | 62 | 11 |
| Telmisartan | Telmisartan | 61 | 14 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 60 | 25 |
| Nifedipine Er | Nifedipine | 60 | 11 |
| Sertraline Hcl | Sertraline Hcl | 59 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 54 | 15 |
| Glipizide Er | Glipizide | 54 | suppressed |
| Topiramate | Topiramate | 54 | suppressed |
| Levetiracetam Er | Levetiracetam | 53 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 51 | 14 |
| Sotalol | Sotalol Hcl | 50 | suppressed |
| Indapamide | Indapamide | 49 | 12 |
| Promethazine Hcl | Promethazine Hcl | 48 | 34 |
| Diltiazem Hcl | Diltiazem Hcl | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 47 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Prednisone | Prednisone | 41 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Gemtesa | Vibegron | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 19 |
| Hydrocortisone | Hydrocortisone | 37 | 11 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | 12 |
| Estradiol | Estradiol | 35 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 28 | suppressed |
| Olanzapine | Olanzapine | 27 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 16 |
| Pulmicort Flexhaler | Budesonide | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 12 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,340.27 · 85 records | Aimmune Therapeutics, Inc. | AIRSUPRA, AURYON LASER SYSTEM 100-120 VAC, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, IBSRELA, JARDIANCE, LINZESS, Ozempic, REXULTI, VOWST, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error